Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
38
ICCM Quote, Financials, Valuation and Earnings
Last price:
$0.67
Seasonality move
:
25.42%
Day range:
$0.65 - $0.68
52-week range:
$0.59 - $1.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.65x
P/B ratio:
5.00x
Volume:
274.6K
Avg. volume:
397.4K
1-year change:
-41.31%
Market cap:
$46.5M
Revenue:
$3.3M
EPS (TTM):
-$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
$2.2M | -$0.04 | 2.97% | -49.43% | $3.13 |
|
INBS
Intelligent Bio Solutions, Inc.
|
$1.4M | -- | 160.36% | -- | -- |
|
LAB
Standard BioTools, Inc.
|
$18.6M | -$0.02 | -60.4% | -72.53% | $1.65 |
|
LNSR
LENSAR, Inc.
|
$18.6M | -$0.09 | 30.98% | -90.51% | $15.00 |
|
NNOX
Nano-X Imaging Ltd.
|
$5M | -$0.14 | 33.13% | -35.84% | $8.15 |
|
XYLO
Xylo Technologies Ltd.
|
-- | -- | -- | -- | $9.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
$0.67 | $3.13 | $46.5M | -- | $0.00 | 0% | 13.65x |
|
INBS
Intelligent Bio Solutions, Inc.
|
$6.14 | -- | $5.9M | -- | $0.00 | 0% | 12.21x |
|
LAB
Standard BioTools, Inc.
|
$1.63 | $1.65 | $626.8M | -- | $0.00 | 0% | 4.80x |
|
LNSR
LENSAR, Inc.
|
$12.01 | $15.00 | $143.5M | -- | $0.00 | 0% | 2.41x |
|
NNOX
Nano-X Imaging Ltd.
|
$2.99 | $8.15 | $195.5M | -- | $0.00 | 0% | 15.33x |
|
XYLO
Xylo Technologies Ltd.
|
$5.07 | $9.00 | $6.5M | -- | $3.94 | 0% | 0.13x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
3% | -1.540 | 0.41% | 1.76x |
|
INBS
Intelligent Bio Solutions, Inc.
|
35.02% | 2.804 | 21.48% | 0.47x |
|
LAB
Standard BioTools, Inc.
|
6.41% | 0.589 | 5.49% | 1.93x |
|
LNSR
LENSAR, Inc.
|
-31.16% | -1.208 | 1.79% | 0.65x |
|
NNOX
Nano-X Imaging Ltd.
|
4.79% | 0.676 | 3.26% | 3.82x |
|
XYLO
Xylo Technologies Ltd.
|
29.91% | -0.433 | 154.75% | 0.95x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
$277K | -$3.8M | -195.32% | -217.45% | -451.29% | -$3.1M |
|
INBS
Intelligent Bio Solutions, Inc.
|
$214.9K | -$2.9M | -213.68% | -255.54% | -263.64% | -$2.9M |
|
LAB
Standard BioTools, Inc.
|
$9.5M | -$23.5M | -22.34% | -24.44% | -120.02% | -$23.1M |
|
LNSR
LENSAR, Inc.
|
$5.8M | -$7.6M | -684.94% | -1013.45% | -52.95% | -$3.5M |
|
NNOX
Nano-X Imaging Ltd.
|
-$3M | -$14.2M | -31.33% | -32.75% | -412.88% | -$13.9M |
|
XYLO
Xylo Technologies Ltd.
|
-- | -- | -40.15% | -51.7% | -- | -- |
IceCure Medical Ltd. vs. Competitors
-
Which has Higher Returns ICCM or INBS?
Intelligent Bio Solutions, Inc. has a net margin of -454% compared to IceCure Medical Ltd.'s net margin of -269.38%. IceCure Medical Ltd.'s return on equity of -217.45% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.32.59% -$0.06 $9.6M INBSIntelligent Bio Solutions, Inc.19.33% -$0.35 $5.4M -
What do Analysts Say About ICCM or INBS?
IceCure Medical Ltd. has a consensus price target of $3.13, signalling upside risk potential of 363.03%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 1854.4%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than IceCure Medical Ltd., analysts believe Intelligent Bio Solutions, Inc. is more attractive than IceCure Medical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 INBSIntelligent Bio Solutions, Inc.0 0 0 -
Is ICCM or INBS More Risky?
IceCure Medical Ltd. has a beta of 0.997, which suggesting that the stock is 0.34999999999999% less volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ICCM or INBS?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or INBS?
IceCure Medical Ltd. quarterly revenues are $850K, which are smaller than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. IceCure Medical Ltd.'s net income of -$3.9M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 13.65x versus 12.21x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.13.65x -- $850K -$3.9M INBSIntelligent Bio Solutions, Inc.12.21x -- $1.1M -$3M
-
Which has Higher Returns ICCM or LAB?
Standard BioTools, Inc. has a net margin of -454% compared to IceCure Medical Ltd.'s net margin of -162.05%. IceCure Medical Ltd.'s return on equity of -217.45% beat Standard BioTools, Inc.'s return on equity of -24.44%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.32.59% -$0.06 $9.6M LABStandard BioTools, Inc.48.51% -$0.09 $427M -
What do Analysts Say About ICCM or LAB?
IceCure Medical Ltd. has a consensus price target of $3.13, signalling upside risk potential of 363.03%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.65 which suggests that it could fall by -4.91%. Given that IceCure Medical Ltd. has higher upside potential than Standard BioTools, Inc., analysts believe IceCure Medical Ltd. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 LABStandard BioTools, Inc.1 2 0 -
Is ICCM or LAB More Risky?
IceCure Medical Ltd. has a beta of 0.997, which suggesting that the stock is 0.34999999999999% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.585%.
-
Which is a Better Dividend Stock ICCM or LAB?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or LAB?
IceCure Medical Ltd. quarterly revenues are $850K, which are smaller than Standard BioTools, Inc. quarterly revenues of $19.6M. IceCure Medical Ltd.'s net income of -$3.9M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 13.65x versus 4.80x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.13.65x -- $850K -$3.9M LABStandard BioTools, Inc.4.80x -- $19.6M -$31.7M
-
Which has Higher Returns ICCM or LNSR?
LENSAR, Inc. has a net margin of -454% compared to IceCure Medical Ltd.'s net margin of -25.94%. IceCure Medical Ltd.'s return on equity of -217.45% beat LENSAR, Inc.'s return on equity of -1013.45%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.32.59% -$0.06 $9.6M LNSRLENSAR, Inc.40.56% -$0.31 -$9.2M -
What do Analysts Say About ICCM or LNSR?
IceCure Medical Ltd. has a consensus price target of $3.13, signalling upside risk potential of 363.03%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 24.9%. Given that IceCure Medical Ltd. has higher upside potential than LENSAR, Inc., analysts believe IceCure Medical Ltd. is more attractive than LENSAR, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 LNSRLENSAR, Inc.0 2 0 -
Is ICCM or LNSR More Risky?
IceCure Medical Ltd. has a beta of 0.997, which suggesting that the stock is 0.34999999999999% less volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.53%.
-
Which is a Better Dividend Stock ICCM or LNSR?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or LNSR?
IceCure Medical Ltd. quarterly revenues are $850K, which are smaller than LENSAR, Inc. quarterly revenues of $14.3M. IceCure Medical Ltd.'s net income of -$3.9M is lower than LENSAR, Inc.'s net income of -$3.7M. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 13.65x versus 2.41x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.13.65x -- $850K -$3.9M LNSRLENSAR, Inc.2.41x -- $14.3M -$3.7M
-
Which has Higher Returns ICCM or NNOX?
Nano-X Imaging Ltd. has a net margin of -454% compared to IceCure Medical Ltd.'s net margin of -396.98%. IceCure Medical Ltd.'s return on equity of -217.45% beat Nano-X Imaging Ltd.'s return on equity of -32.75%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.32.59% -$0.06 $9.6M NNOXNano-X Imaging Ltd.-86.42% -$0.21 $164.6M -
What do Analysts Say About ICCM or NNOX?
IceCure Medical Ltd. has a consensus price target of $3.13, signalling upside risk potential of 363.03%. On the other hand Nano-X Imaging Ltd. has an analysts' consensus of $8.15 which suggests that it could grow by 172.58%. Given that IceCure Medical Ltd. has higher upside potential than Nano-X Imaging Ltd., analysts believe IceCure Medical Ltd. is more attractive than Nano-X Imaging Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 NNOXNano-X Imaging Ltd.4 0 0 -
Is ICCM or NNOX More Risky?
IceCure Medical Ltd. has a beta of 0.997, which suggesting that the stock is 0.34999999999999% less volatile than S&P 500. In comparison Nano-X Imaging Ltd. has a beta of 1.070, suggesting its more volatile than the S&P 500 by 6.959%.
-
Which is a Better Dividend Stock ICCM or NNOX?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nano-X Imaging Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Nano-X Imaging Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or NNOX?
IceCure Medical Ltd. quarterly revenues are $850K, which are smaller than Nano-X Imaging Ltd. quarterly revenues of $3.4M. IceCure Medical Ltd.'s net income of -$3.9M is higher than Nano-X Imaging Ltd.'s net income of -$13.7M. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Nano-X Imaging Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 13.65x versus 15.33x for Nano-X Imaging Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.13.65x -- $850K -$3.9M NNOXNano-X Imaging Ltd.15.33x -- $3.4M -$13.7M
-
Which has Higher Returns ICCM or XYLO?
Xylo Technologies Ltd. has a net margin of -454% compared to IceCure Medical Ltd.'s net margin of --. IceCure Medical Ltd.'s return on equity of -217.45% beat Xylo Technologies Ltd.'s return on equity of -51.7%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.32.59% -$0.06 $9.6M XYLOXylo Technologies Ltd.-- -- $22.4M -
What do Analysts Say About ICCM or XYLO?
IceCure Medical Ltd. has a consensus price target of $3.13, signalling upside risk potential of 363.03%. On the other hand Xylo Technologies Ltd. has an analysts' consensus of $9.00 which suggests that it could grow by 77.52%. Given that IceCure Medical Ltd. has higher upside potential than Xylo Technologies Ltd., analysts believe IceCure Medical Ltd. is more attractive than Xylo Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 XYLOXylo Technologies Ltd.1 0 0 -
Is ICCM or XYLO More Risky?
IceCure Medical Ltd. has a beta of 0.997, which suggesting that the stock is 0.34999999999999% less volatile than S&P 500. In comparison Xylo Technologies Ltd. has a beta of 0.148, suggesting its less volatile than the S&P 500 by 85.241%.
-
Which is a Better Dividend Stock ICCM or XYLO?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xylo Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $3.94 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Xylo Technologies Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or XYLO?
IceCure Medical Ltd. quarterly revenues are $850K, which are larger than Xylo Technologies Ltd. quarterly revenues of --. IceCure Medical Ltd.'s net income of -$3.9M is higher than Xylo Technologies Ltd.'s net income of --. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Xylo Technologies Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 13.65x versus 0.13x for Xylo Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.13.65x -- $850K -$3.9M XYLOXylo Technologies Ltd.0.13x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
